Summary
Background Patients with metastatic colorectal cancer (mCRC) who progress on standard therapies may be eligible for phase I trials. To better delineate the risk-benefit ratio, we assessed toxicities, clinical outcomes and prognostic factors. Methods Records of mCRC patients on phase I trials at our institution over 18 years were reviewed. Univariable (UVA) and multivariable analyses (MVA) were undertaken and a prognostic model developed. Results There were 187 enrollments on 37 phase I trials. Median age was: 59 (29–83) years and number of prior therapies: 3 (0–8). The clinical benefit rate (CBR): response (5.6%) + stable disease, was 43.1%. Median progression free survival (PFS) and overall survival (OS) was 7.7 weeks and 43.7 weeks, respectively. The MVA identified age > 60 years (HR 1.63, p < 0.004), albumin<3.5 g/dL (HR 3.69, p < 0.001), direct bilirubin>ULN (HR1.69, p < 0.01), and WBC ≥ 5.2 k/uL (HR 1.97, p < 0.001) as negative prognostic factors. A risk score based on the MVA revealed that patients with a score of 0–1 had an improved OS (58.7 weeks) compared to a score of 2 (49.9 weeks, p < 0.01) and 3 (14.1 weeks, p < 0.001). Conclusions Phase 1 trials may offer similar or better clinical outcome for mCRC patients than standard third line therapies; the prognostic model could assist in selecting appropriate patients.
Similar content being viewed by others
References
SEER Cancer Stat Facts: Colorectal Cancer [Internet]. Bethesda, MD: National Cancer Institute. 1975 – [cited 2017 Oct 9]. Available from: http://seer.cancer.gov/statfacts/html/colorect.html
Hoff PM, Ansari R, Batist R, Cox J, Kocha W, Kuperminc M et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-batran SE et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075
Venook A, Niedzwiecki D, Lenz H, Mahoney M, Innocenti F, O’Neil B et al (2014) CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy. Ann Oncol 25:1–41 (abstr LBA10)
U.S. Food and Drug Administration: FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Available at: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm. Accessed May 30, 2018
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142). Lancet Oncol 18:1182–1191
Arkenau H, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2008) Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 98(6):1029–1033
Arkenau H, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I et al (2009) Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27:2692–2696
Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, Chauvin F, Droz JP, Philip T, Clavel M (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11(2):151–156
Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 89(7):1166–1171
Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magné N, Pignon JP, Vassal G, Armand JP, Soria JC (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19(4):787–792
Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R (2012) Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 18(10):2922–2929
Yamamoto N, Tamura T, Fukuoka M, Saijo N (1999) Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 15(4):737–741
Arkenau H, Olmos D, Ang JE, Barriuso J, Karavasillis V, Ashley S et al (2008) 90-days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 44:1536–1540
Chau NG, Florescu A, Chan K, Wang L, Chen EX, Bedard P et al (2011) Early mortality and overall survival in oncology phase 1 trial participants: can we improve patient selection? BMC Cancer 11(426):1–10
Grothey A, Van Custem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312
Mayer RJ, Van Custem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal Cancer. N Engl J Med 372:1909–1919
Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksa H, Needl MA (2001) Cetuximab (IMC-225) plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor (abstract). Proc Am Soc Clin Oncol 3a:20
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA III (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417
Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296
Heng DY, Xie W, Regan M, Warren MA, Golshayan AR, Sahi C et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799
Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O’Brien S, Kuf M et al (1994) Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 74:1965–1973
Penel N, Vanseymortier M, Bonneterre ME, Clisant S, Dansin E, Vendel Y, Beuscart R, Bonneterre J (2008) Prognostic factors among cancer patients with good performance status screened for phase I trials. Investig New Drugs 26:53–58
Penel N, Delord JP, Bonneterre ME, Bachelot T, Ray-Coquard I, Blay JY, Pascal LB, Borel C, Filleron T, Adenis A, Bonneterre J (2010) Development and validation of a model that predicts early death among cancer patients participating in phase 1 clinical trials investigating cytotoxics. Investig New Drugs 28:76–82
Fussenich LM, Desar IME, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN et al (2011) A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 47:1152–1160
Stavraka C, Pinato DJ, Turnbull SJ, Flynn MJ, Forster MD, O’Cathail SM et al (2013) Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials. Cancer 120(1):262–270
Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A (2018) Clinical outcomes of patients with gastrointestinal malignancies participating in phase I clinical trials. Am J Clin Oncol 41(2):133–139
Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R (2012) Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Canc 11:297–303
So KA, Hong JH, Jin HM, Kim JW, Song JY, Lee JK, Lee NW (2014) The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study. Gynecol Oncol 132(3):551–555
Mabuchi S, Matsumoto Y, Hamasaki T, Kawano M, Hisamatsu T, Mutch DG, Kimura T (2012) Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer. Int J Gynecol Cancer 22(9):1545–1551
Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T (2009) Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. Anticancer Res 29(7):2687–2690
Clarke CN, Kopetz ES (2015) BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointestinal Oncol 6(6):660–667
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
Each individual clinical trial from which data was extracted was approved by the ethics committee of Montefiore Medical Center. Each individual trial was performed in accordance with the 1964 Helsinki declaration and its later amendments.
Informed consent
All patients entering the clinical trials have signed the informed consent document.
Electronic supplementary material
Supplementary Table A1
(DOC 41 kb)
Summary of hematologic and nonhematologic toxicities of patients on phase 1 trials. Grading of toxicity based on CTCAE version at the time of study entry. Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events.
Rights and permissions
About this article
Cite this article
Kam, A.E., Pendurti, G., Shah, U.H. et al. Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials. Invest New Drugs 37, 490–497 (2019). https://doi.org/10.1007/s10637-018-0675-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-018-0675-9